T1	Participants 482 576	Thirty nonbleeding patients with international normalized ratios (INRs) ranging from 6.0-10.0.
T2	Participants 591 687	Patients were randomized to receive either a single oral dose of phytonadione 2.5 mg or placebo.
T3	Participants 1606 1758	patients at high risk for bleeding in whom the benefit of prompt INR reduction would outweigh the thromboembolic risk associated with INR overcorrection
T4	Participants 1515 1558	asymptomatic patients with INRs of 6.0-10.0
